Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort Study

Jon Salmanton-García,Oliver A. Cornely,Jannik Stemler,Aleksandra Barac,Jörg Steinmann,Alena Siváková,Emin Halis Akalin,Sevtap Arikan-Akdagli,Laura Loughlin,Cristina Toscano,Manjusha Narayanan,Benedict Rogers,Birgit Willinger,Deniz Akyol,Emmanuel Roilides,Katrien Lagrou,Malgorzata Mikulska,Blandine Denis,Diane Ponscarme,Urlike Scharmann,Alpay Azap,Deborah Lockhart,Tihana Bicanic,Florian Kron,Nurettin Erben,Riina Rautemaa-Richardson,Anna L. Goodman,Carolina Garcia-Vidal,Cornelia Lass-Flörl,Jean-Pierre Gangneux,Lucia Taramasso,Maite Ruiz,Yael Schick,Eric Van Wijngaerden,Christopher Milacek,Daniele Roberto Giacobbe,Clare Logan,Emily Rooney,Andrea Gori,Murat Akova,Matteo Bassetti,Martin Hoenigl,Philipp Koehler

DOI: https://doi.org/10.1016/j.jinf.2024.106229

IF: 28.2

2024-07-18

Journal of Infection

Abstract:Introduction Despite antifungal advancements, candidaemia still has a high mortality rate of up to 40%. The ECMM Candida III study in Europe investigated the changing epidemiology and outcomes of candidaemia for better understanding and management of these infections. Methods In this observational cohort study, participating hospitals enrolled the first ten consecutive adults with blood culture-proven candidemia. Collected data included patient demographics, risk factors, hospital stay duration (follow-up of 90 days), diagnostic procedures, causative Candida spp., management details, and outcome. Controls were included in a 1:1 fashion from the same hospitals. The matching process ensured similarity in age (10-year range), primary underlying disease, hospitalization in intensive care versus non-ICU ward, and major surgery within 2 weeks before candidemia between cases and controls. Overall and attributable mortality were described and a survival probability for cases and controls was performed. Results One hundred seventy-one pairs consisting of patients with candidemia and matched controls from 28 institutions were included. In those with candidemia, overall mortality was 40.4%. Attributable mortality was 18.1% overall but differed between causative Candida species (7.7% for Candida albicans , 23.7% for Candida glabrata/Nakaseomyces glabratus , 7.7% for Candida parapsilosis and 63.6% for Candida tropicalis ). Regarding risk factors, presence of a central venous catheter, total parenteral nutrition and acute or chronic renal disease were significantly more common in cases versus controls. Duration of hospitalization, and especially that of ICU stay was significantly longer in candidemia cases (20 (IQR 10-33) vs 15 days (IQR 7-28); p=0.004). Conclusions Although overall and attributable mortality in this subgroup analysis of matched case/control pairs remains high, the attributable mortality appears to have decreased in comparison to historical cohorts. This decrease may be driven by improved prognosis of Candida albicans and Candida parapsilosis candidemia; whereas candidemia due to other Candida spp. exhibits a much higher attributable mortality.

infectious diseases

What problem does this paper attempt to address?

Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort Study

Clinical analysis of 14 cases of candidemia

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Clinical Features, Strain Distribution, Antifungal Resistance and Prognosis of Patients with Non-albicans Candidemia: A Retrospective Observational Study.

Incidence, Clinical Characteristics, Risk Factors and Outcomes of Patients with Mixed Candida/bacterial Bloodstream Infections: a Retrospective Study

Epidemiology, Species Distribution, Antifungal Susceptibility and Mortality Risk Factors of Candidemia among Critically Ill Patients: a Retrospective Study from 2011 to 2017 in a Teaching Hospital in China

Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV

Independent risk factors for mortality in critically ill patients with candidemia on Italian Internal Medicine Wards

Role of source control in critically ill candidemic patients: a multicenter retrospective study

Understanding clinical outcomes and factors influencing mortality in intensive care unit patients with COVID‐19‐associated candidemia

Clinical Features and Prognostic Risk Factors of Candidemia in Non-Intensive Care Unit Wards

Epidemiology, species distribution, and predictive factors for mortality of candidemia in adult surgical patients

Factors influencing outcomes in candidemia: A retrospective study of patients in a Swedish county

Mortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis

Epidemiology, clinical characteristics, outcome and biofilm forming properties in candidaemia: A single‐centre retrospective 4‐year analysis from Hungary

Epidemiological Assessment and Risk Factors for Mortality of Bloodstream Infections by Candida sp. and the Impact of the COVID-19 Pandemic Era

[Analysis of Clinical Characteristics and Risk Factors Associated with Prognosis of Patients with Candidemia].

Antibiotics exposure, risk factors, and outcomes with Candida albicans and non-Candida albicans candidemia. Results from a multi-center study.

Epidemiology, risk factors, treatment and outcome of Candida bloodstream infections because of Candida albicans and Candida non‐albicans in two district general hospitals in the United Kingdom

Nosocomial Bloodstream Infection Due to Candida spp. in China: Species Distribution, Clinical Features, and Outcomes

Analysis of risk factors and prognosis of patients with candidemia